Home Tags IMGN529

Tag: IMGN529

Debiopharm Acquires Phase II IMGN529 from ImmunoGen

Debiopharm International, a Swiss biopharmaceutical company, has confirmed that it has acquired ImmunoGen's IMGN529, also known as Debio 1562 or naratuximab emtansine, a clinical-stage anti-CD37 antibody-drug...

AACR 2017: Nine Presentations Feature ImmunoGen’s Approch to ADC development

Earlier today, ImmunoGen, a company at the forefront of antibody-drug conjugates (ADC-) development for the treatment of cancer, announced that nine abstracts highlighting the...

X